The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
Site Search
Showing 1 - 2 of 2 results
Press Release
|
March 29, 2022
|
4 min read
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
Press Release
|
Jan. 4, 2022
|
4 min read